

# Ilona Kovalszky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2480583/publications.pdf>

Version: 2024-02-01

165  
papers

4,932  
citations

71102

41  
h-index

138484

58  
g-index

173  
all docs

173  
docs citations

173  
times ranked

6747  
citing authors

#	ARTICLE	IF	CITATIONS
1	SPOCK1 Promotes the Development of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 819883.	2.8	9
2	The effects of sulfated hyaluronan in breast, lung and colorectal carcinoma and monocytes/macrophages cells: Its role in angiogenesis and tumor progression. <i>IUBMB Life</i> , 2022, 74, 927-942.	3.4	5
3	Expression of glycosaminoglycans in cirrhotic liver and hepatocellular carcinoma—a pilot study including etiology. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 3837-3846.	3.7	7
4	SPOCK1 with unexpected function. The start of a new career. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C688-C693.	4.6	4
5	Proteoglycans: Systems-Level Insight into Their Expression in Healthy and Diseased Placentas. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5798.	4.1	8
6	Proteomic Analysis of Lung Cancer Types—A Pilot Study. <i>Cancers</i> , 2022, 14, 2629.	3.7	7
7	Syndecan-1 in liver pathophysiology. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C289-C294.	4.6	7
8	EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. <i>Translational Lung Cancer Research</i> , 2021, 10, 662-674.	2.8	17
9	Overexpression of Human Syndecan-1 Protects against the Diethylnitrosamine-Induced Hepatocarcinogenesis in Mice. <i>Cancers</i> , 2021, 13, 1548.	3.7	7
10	Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis. <i>Pathology and Oncology Research</i> , 2020, 26, 3-15.	1.9	75
11	Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 727-734.	1.9	3
12	Syndecan-1 in Liver Diseases. <i>Pathology and Oncology Research</i> , 2020, 26, 813-819.	1.9	27
13	Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 253-261.	1.9	4
14	Chronic Hyperglycaemia Induced Alterations of Hepatic Stellate Cells Differ from the Effect of TGF $\beta$ 1, and Point toward Metabolic Stress. <i>Pathology and Oncology Research</i> , 2020, 26, 291-299.	1.9	3
15	KIT Mutation Incidence and Pattern of Melanoma in Central Europe. <i>Pathology and Oncology Research</i> , 2020, 26, 17-22.	1.9	13
16	Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. <i>Biomolecules</i> , 2020, 10, 1356.	4.0	6
17	Serum and tissue syndecan-1 levels in renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 1167-1176.	1.4	1
18	Proteomic identification of Placental Protein 1 (PP1), PP8, and PP22 and characterization of their placental expression in healthy pregnancies and in preeclampsia. <i>Placenta</i> , 2020, 99, 197-207.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Prevalence of APC and PTEN Alterations in Urachal Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 2773-2781.	1.9	10
20	Decreased Expression of ZNF554 in Gliomas is Associated with the Activation of Tumor Pathways and Shorter Patient Survival. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5762.	4.1	5
21	Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. <i>Diagnostics</i> , 2020, 10, 864.	2.6	6
22	The Protective Role of Decorin in Hepatic Metastasis of Colorectal Carcinoma. <i>Biomolecules</i> , 2020, 10, 1199.	4.0	12
23	Cross-testing of major molecular markers indicates distinct pathways of tumorigenesis in gastric adenocarcinomas and synchronous gastrointestinal stromal tumors. <i>Scientific Reports</i> , 2020, 10, 22212.	3.3	5
24	Protective Role of Decorin in Primary Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 645.	2.8	21
25	Two ways of epigenetic silencing of TFPI2 in cervical cancer. <i>PLoS ONE</i> , 2020, 15, e0234873.	2.5	6
26	Aberrant Expression of Syndecan-1 in Cervical Cancers. <i>Pathology and Oncology Research</i> , 2020, 26, 2255-2264.	1.9	8
27	Salt gradient chromatographic separation of chondroitin sulfate disaccharides. <i>Journal of Chromatography A</i> , 2020, 1619, 460979.	3.7	11
28	Decorin in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1272, 17-38.	1.6	17
29	Tumor-specific inhibitory action of decorin on different hepatoma cell lines. <i>Cellular Signalling</i> , 2019, 62, 109354.	3.6	14
30	Increased placental expression of Placental Protein 5 (PP5) / Tissue Factor Pathway Inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: Relevance to impaired trophoblast invasion?. <i>Placenta</i> , 2019, 76, 30-39.	1.5	18
31	Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. <i>Acta Oncologica</i> , 2019, 58, 1087-1094.	1.8	22
32	MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2019, 25, 1103-1109.	1.9	8
33	The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors. <i>Pathology and Oncology Research</i> , 2019, 25, 217-224.	1.9	13
34	Proteomic identification of membrane-associated placental protein 4 (MP4) as perlecan and characterization of its placental expression in normal and pathologic pregnancies. <i>PeerJ</i> , 2019, 7, e6982.	2.0	6
35	Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGF $\beta$ 1 action and upregulating MMP14. <i>Matrix Biology</i> , 2018, 68-69, 474-489.	3.6	31
36	Extracellular matrix functions in lung cancer. <i>Matrix Biology</i> , 2018, 73, 105-121.	3.6	42

#	ARTICLE	IF	CITATIONS
37	Chemodiversity of Cirsium fruits: Antiproliferative lignans, neolignans and sesqueneolignans as chemotaxonomic markers. <i>FÄ-toterapÄ-Äç</i> , 2018, 127, 413-419.	2.2	8
38	<scp>P</scp>athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. <i>International Journal of Cancer</i> , 2018, 143, 1764-1773.	5.1	44
39	Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 312.e9-312.e15.	1.6	23
40	NSCLC molecular testing in Central and Eastern European countries. <i>BMC Cancer</i> , 2018, 18, 269.	2.6	28
41	Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse. <i>BMC Cancer</i> , 2018, 18, 157.	2.6	13
42	Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. <i>Frontiers in Immunology</i> , 2018, 9, 1661.	4.8	146
43	Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas. <i>Pathology and Oncology Research</i> , 2017, 23, 633-641.	1.9	19
44	KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. <i>Scientific Reports</i> , 2017, 7, 39721.	3.3	62
45	Response of Hepatic Stellate Cells to TGFB1 Differs from the Response of Myofibroblasts. Decorin Protects against the Action of Growth Factor. <i>Pathology and Oncology Research</i> , 2017, 23, 287-294.	1.9	4
46	Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. <i>Journal of Cancer</i> , 2017, 8, 162-173.	2.5	7
47	Soluble syndecanâ€ł (SDC1) serum level as an independent preâ€operative predictor of cancerâ€specific survival in prostate cancer. <i>Prostate</i> , 2016, 76, 977-985.	2.3	39
48	Fluorescence activated cell sorting followed by small RNA sequencing reveals stable microRNA expression during cell cycle progression. <i>BMC Genomics</i> , 2016, 17, 412.	2.8	10
49	BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters?. <i>Pathobiology</i> , 2016, 83, 1-12.	3.8	9
50	Polyvinyl alcohol nanofiber formulation of the designer antimicrobial peptide APO sterilizes <i>Acinetobacter baumannii</i> -infected skin wounds in mice. <i>Amino Acids</i> , 2016, 48, 203-211.	2.7	42
51	Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. <i>Oncotarget</i> , 2016, 7, 39293-39301.	1.8	45
52	Proteoglycans in liver cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 379.	3.3	82
53	Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. <i>American Journal of Cancer Research</i> , 2016, 6, 2041-2053.	1.4	30
54	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 738-746.	1.1	70

#	ARTICLE	IF	CITATIONS
55	Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. <i>PLoS ONE</i> , 2015, 10, e0133836.	2.5	42
56	Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression. <i>BMC Cancer</i> , 2015, 15, 256.	2.6	101
57	A simple and effective enrichment process of the antiproliferative lignan arctigenin based on the endogenous enzymatic hydrolysis of <i>Serratula tinctoria</i> and <i>Arctium lappa</i> fruits. <i>Process Biochemistry</i> , 2015, 50, 2281-2288.	3.7	12
58	DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer. <i>BMC Cancer</i> , 2015, 15, 736.	2.6	53
59	Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling. <i>Biopolymers</i> , 2015, 104, 156-166.	2.4	20
60	Activation of Villous Trophoblastic p38 and ERK1/2 Signaling Pathways in Preterm Preeclampsia and HELLP Syndrome. <i>Pathology and Oncology Research</i> , 2015, 21, 659-668.	1.9	36
61	Ultrastructure and composition of thrombi in coronary and peripheral artery disease: Correlations with clinical and laboratory findings. <i>Thrombosis Research</i> , 2015, 135, 760-766.	1.7	18
62	Endogenous enzyme-hydrolyzed fruit of <i>Cirsium brachycephalum</i> : Optimal source of the antiproliferative lignan trachelogenin regulating the Wnt/ $\beta^2$ -Catenin signaling pathway in the SW480 colon adenocarcinoma cell line. <i>FÄ-toterapÄ-Äç</i> , 2015, 100, 19-26.	2.2	18
63	Chronic Hyperglycemia Induces Trans-Differentiation of Human Pancreatic Stellate Cells and Enhances the Malignant Molecular Communication with Human Pancreatic Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0128059.	2.5	24
64	Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model. <i>American Journal of Cancer Research</i> , 2015, 5, 3645-58.	1.4	10
65	Proteoglycans/Glycosaminoglycans: From Basic Research to Clinical Practice. <i>BioMed Research International</i> , 2014, 2014, 1-2.	1.9	6
66	Development of second generation peptides modulating cellular adiponectin receptor responses. <i>Frontiers in Chemistry</i> , 2014, 2, 93.	3.6	36
67	Increased placental expression of cannabinoid receptor 1 in preeclampsia: an observational study. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 395.	2.4	33
68	Placental Protein 13 (PP13) Äç, Äœ A Placental Immunoregulatory Galectin Protecting Pregnancy. <i>Frontiers in Immunology</i> , 2014, 5, 348.	4.8	90
69	Heparin and Liver Heparan Sulfate Can Rescue Hepatoma Cells from Topotecan Action. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	7
70	Decorin deficiency promotes hepatic carcinogenesis. <i>Matrix Biology</i> , 2014, 35, 194-205.	3.6	71
71	Nuclear translocation of heparan sulfate proteoglycans and their functional significance. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 2491-2497.	2.4	33
72	Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 917-932.	5.4	23

#	ARTICLE	IF	CITATIONS
73	The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor. <i>Amino Acids</i> , 2014, 46, 873-882.	2.7	20
74	Treatment of Refractory Hairy Cell Leukemia with a BRAF-inhibitor: Lessons to be Learnt. <i>Pathology and Oncology Research</i> , 2014, 20, 973-980.	1.9	8
75	Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. <i>Human Pathology</i> , 2014, 45, 674-682.	2.0	49
76	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 1819-1828.	2.8	68
77	Lack of Matrilin-2 Favors Liver Tumor Development via Erk1/2 and GSK-3 $\beta$ Pathways In Vivo. <i>PLoS ONE</i> , 2014, 9, e93469.	2.5	12
78	Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. <i>World Journal of Gastroenterology</i> , 2014, 20, 15343.	3.3	25
79	EGFR mutations in lung adenocarcinoma: Epidemiology and clinical relevance of common versus rare mutations.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19067-e19067.	1.6	0
80	Abstract 422: DNA hypermethylation or upregulated miRNA21 expression potentially leads to decreased mRNA expression of COL1A2, SFRP2, SOCS3, BCL2, MAL and PTGS2 in left-sided colorectal adenoma and cancer. , 2014, , .		0
81	Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 445-458.	2.8	42
82	Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity. <i>Peptides</i> , 2013, 44, 127-134.	2.4	33
83	Curcumin targets fibroblast-tumor cell interactions in oral squamous cell carcinoma. <i>Experimental Cell Research</i> , 2013, 319, 800-809.	2.6	44
84	Molecular Characteristics of Fibrolamellar Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2013, 19, 63-70.	1.9	21
85	Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 191-200.	4.4	16
86	Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. <i>FEBS Journal</i> , 2013, 280, 2150-2164.	4.7	50
87	Utilisation of fluorescent multiplex PCR and laser-induced capillary electrophoresis for the diagnosis of Ewing family of tumours in formalin-fixed paraffin-embedded tissues. <i>Journal of Clinical Pathology</i> , 2012, 65, 1112-1118.	2.0	3
88	Decorin-TGF $\beta$ 2 Axis in Hepatic Fibrosis and Cirrhosis. <i>Journal of Histochemistry and Cytochemistry</i> , 2012, 60, 262-268.	2.5	142
89	Syndecan-1 Enhances Proliferation, Migration and Metastasis of HT-1080 Cells in Cooperation with Syndecan-2. <i>PLoS ONE</i> , 2012, 7, e39474.	2.5	36
90	Recent Advances in the Immunohistochemistry- Aided Differential Diagnosis of Benign Versus Malignant Hepatocellular Lesions. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
91	7.5 Structure-function relationship of syndecan-1, with focus on nuclear translocation and tumor cell behavior. , 2012, , 653-676.		0
92	Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma. <i>Experimental Cell Research</i> , 2012, 318, 1517-1527.	2.6	65
93	Genome-Wide Screening of Genes Regulated by DNA Methylation in Colon Cancer Development. <i>PLoS ONE</i> , 2012, 7, e46215.	2.5	37
94	Marked increase of CYP24A1 mRNA level in hepatocellular carcinoma cell lines following vitamin D administration. <i>Anticancer Research</i> , 2012, 32, 4791-6.	1.1	14
95	Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. <i>European Journal of Cancer</i> , 2011, 47, 1578-1584.	2.8	102
96	Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis. <i>Peptides</i> , 2011, 32, 1567-1574.	2.4	35
97	Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. <i>Laboratory Investigation</i> , 2011, 91, 439-451.	3.7	85
98	Tumor-produced, active Interleukin-1 $\beta$ regulates gene expression in carcinoma-associated fibroblasts. <i>Experimental Cell Research</i> , 2011, 317, 2222-2229.	2.6	59
99	No mutation but high mRNA expression of Coxsackie-Adenovirus Receptor was observed in both dilated and ischemic cardiomyopathy. <i>Forensic Science International</i> , 2011, 212, 47-50.	2.2	16
100	Claudins and tricellulin in fibrolamellar hepatocellular carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 679-688.	2.8	32
101	Validation of Circulating MMP-7 Level as an Independent Prognostic Marker of Poor Survival in Urinary Bladder Cancer. <i>Pathology and Oncology Research</i> , 2011, 17, 325-332.	1.9	43
102	Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. <i>BMC Biotechnology</i> , 2011, 11, 90.	3.3	144
103	Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. <i>Biopolymers</i> , 2011, 96, 117-125.	2.4	41
104	Specific Syndecan-1 Domains Regulate Mesenchymal Tumor Cell Adhesion, Motility and Migration. <i>PLoS ONE</i> , 2011, 6, e14816.	2.5	41
105	PP13, Maternal ABO Blood Groups and the Risk Assessment of Pregnancy Complications. <i>PLoS ONE</i> , 2011, 6, e21564.	2.5	45
106	Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains. <i>Cell Proliferation</i> , 2010, 43, 29-40.	5.3	25
107	Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 393-402.	4.4	29
108	Quantitative and Qualitative Alterations of Heparan Sulfate in Fibrogenic Liver Diseases and Hepatocellular Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2010, 58, 429-441.	2.5	70

#	ARTICLE	IF	CITATIONS
109	Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in <i>Acinetobacter baumannii</i> wound infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2416-2422.	3.0	42
110	Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. <i>Human Pathology</i> , 2010, 41, 1310-1319.	2.0	23
111	Contribution of neutrophil elastase to the lysis of obliterative thrombi in the context of their platelet and fibrin content. <i>Thrombosis Research</i> , 2010, 126, e94-e101.	1.7	5
112	Syndecan-1 and FGF-2, but Not FGF Receptor-1, Share a Common Transport Route and Co-Localize with Heparanase in the Nuclei of Mesenchymal Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e7346.	2.5	63
113	Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer. <i>Pathology and Oncology Research</i> , 2009, 15, 193-201.	1.9	32
114	An Immunohistochemical Study of Colon Adenomas and Carcinomas: E-cadherin, Syndecan-1, Ets-1. <i>Pathology and Oncology Research</i> , 2009, 15, 579-587.	1.9	33
115	Agrin and CD34 Immunohistochemistry for the Discrimination of Benign Versus Malignant Hepatocellular Lesions. <i>American Journal of Surgical Pathology</i> , 2009, 33, 874-885.	3.7	50
116	Expression of Matrilin-2 in Liver Cirrhosis and Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2008, 14, 15-22.	1.9	28
117	Triiodothyronine accelerates differentiation of rat liver progenitor cells into hepatocytes. <i>Histochemistry and Cell Biology</i> , 2008, 130, 1005-1014.	1.7	27
118	Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 387-400.	2.8	113
119	Lymphoepithelioma-like carcinoma of the breast: not Epstein-Barr virus“positive, but human papilloma virus“positive. <i>Human Pathology</i> , 2008, 39, 298-301.	2.0	45
120	Angiogenic Switch of Angiotensin-Tie2 System and Its Prognostic Value in Bladder Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 8253-8262.	7.0	44
121	Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. <i>Human Pathology</i> , 2007, 38, 1508-1515.	2.0	45
122	Regulatory role of kinases and phosphatases on the internalisation of caveolae in HepG2 cells. <i>Micron</i> , 2007, 38, 313-320.	2.2	16
123	A Preliminary Comparative Study of the Prognostic Implications of Type 2 Diabetes Mellitus for Patients With Primary Gingival Carcinoma Treated With Surgery and Radiation Therapy. <i>Journal of Oral and Maxillofacial Surgery</i> , 2007, 65, 452-456.	1.2	14
124	Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. <i>Pathology and Oncology Research</i> , 2007, 13, 187-194.	1.9	31
125	Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. <i>Oncology Reports</i> , 2007, 18, 405-9.	2.6	47
126	Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. <i>Laboratory Investigation</i> , 2006, 86, 1149-1160.	3.7	75



#	ARTICLE	IF	CITATIONS
127	Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. <i>Modern Pathology</i> , 2006, 19, 460-469.	5.5	87
128	The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. <i>Virology</i> , 2006, 348, 289-296.	2.4	28
129	Prognostic significance of high-risk HPV status in advanced cervical cancers and pelvic lymph nodes. <i>Gynecologic Oncology</i> , 2006, 100, 570-578.	1.4	38
130	Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. <i>Oral Oncology</i> , 2006, 42, 493-500.	1.5	32
131	Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture. <i>Cell Biology International</i> , 2005, 29, 959-967.	3.0	14
132	Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia. <i>Pathology and Oncology Research</i> , 2005, 11, 26-31.	1.9	30
133	Spatial Distribution of Keratan Sulfate in the Rabbit Cornea Following Photorefractive Keratectomy. <i>Journal of Refractive Surgery</i> , 2005, 21, 485-493.	2.3	5
134	Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix. <i>Anticancer Research</i> , 2005, 25, 805-13.	1.1	7
135	Spatial distribution of keratan sulfate in the rabbit cornea following photorefractive keratectomy. <i>Journal of Refractive Surgery</i> , 2005, 21, 485-93.	2.3	1
136	Phospholipid Barrier to Fibrinolysis. <i>Journal of Biological Chemistry</i> , 2004, 279, 39863-39871.	3.4	14
137	Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single-center experience. <i>Clinical Transplantation</i> , 2004, 18, 580-584.	1.6	53
138	Myosin: a noncovalent stabilizer of fibrin in the process of clot dissolution. <i>Blood</i> , 2003, 101, 4380-4386.	1.4	17
139	Decorin expression in chronic hepatitis C; effect of interferon alpha treatment. , 2003, , 441-449.		0
140	Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. <i>Seminars in Cancer Biology</i> , 2002, 12, 173-186.	9.6	91
141	Expression of a decorin-like molecule in human melanoma. <i>Pathology and Oncology Research</i> , 2001, 7, 260-266.	1.9	12
142	Expression of Decorin, Transforming Growth Factor-beta1, Tissue Inhibitor Metalloproteinase 1 and 2, and Type IV Collagenases in Chronic Hepatitis. <i>American Journal of Clinical Pathology</i> , 2001, 115, 725-735.	0.7	71
143	Increased risk for cancer in multiple myeloma patients and their first-degree relatives. <i>Haematologia</i> , 2001, 31, 45-50.	0.3	3
144	Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulphate. <i>Biochemical Journal</i> , 2000, 350, 245.	3.7	40

#	ARTICLE	IF	CITATIONS
145	Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulphate. <i>Biochemical Journal</i> , 2000, 350, 245-251.	3.7	59
146	CYTOKINE REGULATION OF SYNDECAN EXPRESSION IN CELLS OF LIVER ORIGIN. <i>Cytokine</i> , 2000, 12, 1557-1560.	3.2	21
147	Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment. <i>Journal of Hepatology</i> , 2000, 32, 993-1002.	3.7	12
148	Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. <i>Molecular and Cellular Biochemistry</i> , 1998, 183, 11-23.	3.1	53
149	Altered Proteoglycan Gene Expression in Human Biliary Cirrhosis. <i>Pathology and Oncology Research</i> , 1997, 3, 51-58.	1.9	3
150	Syndecan-1 - A new piece in B-cell puzzle. <i>Pathology and Oncology Research</i> , 1997, 3, 183-191.	1.9	8
151	Role of sinusoidal heparan sulfate proteoglycan in liver metastasis formation. , 1997, 71, 825-831.		16
152	Proteoglycan Gene Expression in Rat Liver after Partial Hepatectomy. <i>Biochemical and Biophysical Research Communications</i> , 1996, 228, 690-694.	2.1	22
153	Marker enzymes of rat chemical hepatocarcinogenesis in human liver tumors. <i>Pathology and Oncology Research</i> , 1996, 2, 56-58.	1.9	3
154	The biological activity of cisplatin and dibromodulcitol in combination therapy. <i>British Journal of Cancer</i> , 1995, 71, 317-321.	6.4	2
155	Role of proteoglycans in tumor progression. <i>Pathology and Oncology Research</i> , 1995, 1, 85-93.	1.9	7
156	Syndecan-1 Gene Expression in Isolated Rat Liver Cells (Hepatocytes, Kupffer Cells, Endothelial and Ito) <i>Tj ETQq0 0 0 rgBT /Overlock 10 1</i>	2.1	12
157	Modification of DENA-induced hepatocarcinogenesis by CCl4 cirrhosis. Comparison of the marker enzyme patterns. <i>Carcinogenesis</i> , 1992, 13, 773-778.	2.8	15
158	Heparan sulfate proteoglycan of human colon: Partial molecular cloning, cellular expression, and mapping of the gene (HSPG2) to the short arm of human chromosome 1. <i>Genomics</i> , 1991, 10, 673-680.	2.9	57
159	Human clathrin heavy chain (CLTC): Partial molecular cloning, expression, and mapping of the gene to human chromosome 17q11-qter. <i>Genomics</i> , 1991, 11, 174-178.	2.9	31
160	Alkaline Phosphatase Activity in Human and Rat Liver Tumors. <i>Oncology</i> , 1991, 48, 144-148.	1.9	4
161	Altered glycosaminoglycan composition in reactive and neoplastic human liver. <i>Biochemical and Biophysical Research Communications</i> , 1990, 167, 883-890.	2.1	39
162	Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern. <i>Journal of Cancer Research and Clinical Oncology</i> , 1989, 115, 554-557.	2.5	17

#	ARTICLE	IF	CITATIONS
163	Morphological and biochemical studies on the effect of agents with liver protecting properties. Experimentelle Pathologie, 1978, 15, 271-287.	0.2	2
164	Deletion analysis of tumor and urinary DNA to detect bladder cancer: Urine supernatant versus urine sediment. Oncology Reports, 0, , .	2.6	23
165	Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update. , 0, , .		1